Efficacy of inhaled N-acetylcysteine(NAC) on lung function and redox balance in idiopathic pulmonary fibrosis(IPF).

Efficacy of inhaled N-acetylcysteine(NAC) on lung function and redox balance in idiopathic pulmonary fibrosis(IPF). - Efficacy of inhaled NAC in IPF.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007663

Enrollment

Registered

2012-04-05

Start date

2009-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic pulmonary fibrosis

Interventions

inhaled NAC mono-therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)From 50 to 80 years-old 2)Patients with informed consent 3)The patients who have never treated. 4)The patients with stage I or stage II disease severity according to the Japanese Respiratory Society criteria.

Exclusion criteria

Exclusion criteria: 1)Secondary interstitial pneumonia 2)Serious complication 3)Serious drug allergy 4)Mental disorder, central nervous system disorders, cerebrovascular disorders 5)Any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator.

Design outcomes

Primary

Measure	Time frame
The changes in respiratory function test before and after the therapy.	—

Secondary

Measure	Time frame
The levels of total GSH(tGSH), oxidized GSH(GSSG), and GSH/GSSG ratio in the peripheral blood, and 8-OHdG in the urine.	—

Countries

Japan

Contacts

Public ContactYoko Muramatsu

Toho University Omori Medical Center Department of Respiratory Medicine

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026